155 related articles for article (PubMed ID: 8475670)
1. Roferon-A in combination with Tigason in cutaneous T-cell lymphomas.
Dreno B; Celerier P; Litoux P
Acta Haematol; 1993; 89 Suppl 1():28-32. PubMed ID: 8475670
[TBL] [Abstract][Full Text] [Related]
2. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas.
Dréno B
Stem Cells; 1993 Jul; 11(4):269-75. PubMed ID: 8401250
[TBL] [Abstract][Full Text] [Related]
3. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma.
Zachariae H; Thestrup-Pedersen K
J Invest Dermatol; 1990 Dec; 95(6 Suppl):206S-208S. PubMed ID: 2258637
[TBL] [Abstract][Full Text] [Related]
4. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
5. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
6. Biological modifiers (etretinate (changed from etetrinate) and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma.
Avilés A; Guzmán R; García EL; Díaz-Maqueo JC
Cancer Biother Radiopharm; 1996 Feb; 11(1):21-4. PubMed ID: 10851517
[TBL] [Abstract][Full Text] [Related]
7. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate.
Dréno B; Claudy A; Meynadier J; Verret JL; Souteyrand P; Ortonne JP; Kalis B; Godefroy WY; Beerblock K; Thill L
Br J Dermatol; 1991 Nov; 125(5):456-9. PubMed ID: 1751352
[TBL] [Abstract][Full Text] [Related]
8. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
Spaccarelli N; Rook AH
Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
[TBL] [Abstract][Full Text] [Related]
9. [Novel treatment modalities in cutaneous T cell lymphoma. Biologic response modifiers].
Marschalkó M
Orv Hetil; 2005 Jun; 146(23):1251-5. PubMed ID: 15988920
[TBL] [Abstract][Full Text] [Related]
10. High dose etretinate and interferon-alpha--a phase I study in squamous cell carcinomas and transitional cell carcinomas.
Roth AD; Morant R; Alberto P
Acta Oncol; 1999; 38(5):613-7. PubMed ID: 10427950
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cutaneous T-cell lymphoma with retinoids.
Zhang C; Duvic M
Dermatol Ther; 2006; 19(5):264-71. PubMed ID: 17014481
[TBL] [Abstract][Full Text] [Related]
12. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
13. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
Straus DJ; Duvic M; Kuzel T; Horwitz S; Demierre MF; Myskowski P; Steckel S
Cancer; 2007 May; 109(9):1799-803. PubMed ID: 17366595
[TBL] [Abstract][Full Text] [Related]
14. Systemic treatment for cutaneous lymphomas.
Mielke V; Staib G; Sterry W
Recent Results Cancer Res; 1995; 139():403-8. PubMed ID: 7597307
[TBL] [Abstract][Full Text] [Related]
15. Mycosis on mycosis fungoides: zoophilic dermatophytosis selectively superimposed on pre-existing cutaneous T-cell lymphoma (mycosis fungoides) plaques.
Capella GL; Altomare GF
Mycoses; 2003 Feb; 46(1-2):67-70. PubMed ID: 12588488
[TBL] [Abstract][Full Text] [Related]
16. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma.
Zhang C; Duvic M
Dermatol Ther; 2003; 16(4):322-30. PubMed ID: 14686975
[TBL] [Abstract][Full Text] [Related]
17. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL).
Burg G; Dummer R
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S41-4. PubMed ID: 11707863
[TBL] [Abstract][Full Text] [Related]
18. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous T cell lymphoma: update of treatment.
Zackheim HS
Dermatology; 1999; 199(2):102-5. PubMed ID: 10559573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
